
    
      Dose finding part: Patients will be recruited to receive combination of defined sorafenib
      dose (2x400mg) with increasing dose of everolimus (2.5mg, 5mg, 7.5mg, 10mg). There will be a
      run-in phase of 14 days of everolimus followed by combination sorafenib+everolimus starting
      from day 15. The combination will be continued as long as it is tolerated by the patient and
      the patient benefits from the treatment according to RECIST criteria. The maximal tolerated
      dose will be establish in 3+3 design. Patients will be recruited sequentially at least 14
      days apart. The next dose level according to 3+3 design will be initiated if all patients on
      the previous dose level reach day 29.

      Extension part: Patients will be treated with a dose of 7,5 mg Everolimus for 14 days (run-in
      phase) and sorafenib 2x 400 mg until progression
    
  